Zentalis Pharmaceuticals, Inc. ZNTL

Rank #1992 · Nasdaq · $0.1B market cap

⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

36.9

P/E

-0.5

P/B

0.41

ROE

-86.7%

Op. Margin

–%

Debt Ratio

28%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -0.5x, P/B 0.41x. Ranks in the top 50% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -86.7%. Ranks in the top 93% of the universe.

Safety ★★★★☆

Excellent

Debt ratio 28%. Ranks in the top 16% of the universe. Under 100% is generally considered a safe level.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	–	$-0.0B	$-0.0B	$0.0B	–	59
2021	–	$-0.0B	$-0.0B	$0.0B	–	100
2022	–	$-0.1B	$-0.1B	$-0.1B	–	-123
2023	–	$-0.2B	$-0.2B	$0.4B	–	24
2024	$0.0B	$-0.2B	$-0.2B	$0.4B	–	26
2025	$0.0B	$-0.3B	$-0.3B	$0.3B	–	28

← See the full screener